Beigene Signs Exclusive License and Development Agreement with Zymeworks (ZW)

 Beigene Signs Exclusive License and Development Agreement with Zymeworks (ZW)

Beigene Signs Exclusive License and Development Agreement with Zymeworks (ZW)

Shots:

  • Beigene to get exclusive development and commercialization rights to ZW’s ZW25 and ZW49 candidates in Asia, New Zealand and Australia (ex. Japan). ZW to receive $40M upfront, $390M milestones and tiered royalties on sales
  • Also, Beigene to get WW rights of ZW’s Azymetric & EFECT platforms, to develop up to three bispecific Abs and ZW to receive $20M upfront, $702M milestone plus royalties on global sales
  • ZW49 is a bispecific pre-clinical candidate targeting two non-overlapping epitopes of HER2. ZW25 is a P-I candidate developed using Azymetric platform, used for binding two non-overlapping epitopes of HER2

Click here to read full press release/ article | Ref: Zymeworks | Image: PMLive

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post